Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

124.03

+0.49 (0.40%)

as of Jul 13, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Jul 13, 2026, 12:00 am

This summary was created by AI, based on 22 opinions in the last 12 months.

Merck & Company (MRK) is regarded as a strong investment opportunity, primarily due to its robust drug pipeline and significant growth potential despite challenges with its blockbuster drug, Keytruda, which is set to go off-patent in 2028. Analysts highlight the company's anticipated increase in sales, particularly from Keytruda and other new drugs in development. While some concerns exist regarding market fluctuations and pricing clarity, a substantial number of experts maintain an optimistic outlook on the stock's performance. With a promising array of drugs poised for release by 2030 and solid financial metrics, including rising cash reserves and share buybacks, MRK is projected to see continued growth, making it a compelling choice for healthcare investors. Expert recommendations suggest a prudent approach to stop-loss levels and target price adjustments.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfeizer, PFE

TOP PICK

Dividend yield is very attractive. You pay very little for the upside.

TOP PICK

Yield is over 3%. Trading around 15 X next year's earnings.

TOP PICK

This late in the cycle, look for stocks that are large, overlooked and underowned. Had a low in 2002 and a higher low at the end of 2003 in a downtrend, still expects to see money going to this group.

WEAK BUY

Have more patent issues than the majority of the big pharmas. Not a lot of catalysts. If you are a real long-term, patient investor, not a bad buy.

BUY

Big pharma stocks should do well in this market. Historically, they do well when rates start to move up.

DON'T BUY

Still under a major downtrend line. Trying to find a base.

TOP PICK

A quiet stock in that not many people are expecting much from them, 7/8% growth this year but you do get a nice 3%+ dividend yield while you wait. Trades at about 15 X earnings. Has a new cholesterol drug coming out this year.

BUY

Has had problems with patent expiry's and drugs in its channel. Gives a 3% dividend yield. Continues to like.

TOP PICK

trading at significantly less than fair value. Bad news on drug development. Dividends at 3.3%

DON'T BUY

Have had tremendous issues. They had to stop production on a couple of drugs that were being tested. Virtually no revenue or earnings coming.

DON'T BUY

When the stock is not participating in a bull market, steer clear. A strong Company and well financed with good products but there is no real excitement. If the market rolls over, it would get hit hard.

BUY

Likes some of the major pharmaceuticals at these levels. Very cheap. Buy and hold.

STRONG BUY

A fantastic time to be buying this stock. If the pharmaceutical industry reverts to anything near normal, this is a huge screaming buy.

BUY

Missed its numbers. Demographics for drugs looks great. At a great price.

DON'T BUY

Not a fan. They don't have a very strong pipeline of promising drugs. Present drugs are facing competition from generics.

Showing 256 to 270 of 305 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)